Published in

American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(33), p. 590-590, 2015

DOI: 10.1200/jco.2015.33.15_suppl.590

Links

Tools

Export citation

Search in Google Scholar

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).

Journal article published in 2015 by Payal Deepak Shah, Sarat Chandarlapaty, Maura N. Dickler, Gary Ulaner, Stephen James Zamora, Valentina Sterlin, Alexia Iasonos, Christina Marie Coughlin, Alex Morozov, Joy Ero, Neal Rosen, Teresa Gilewski, Monica Nancy Fornier, Nancy T. Sklarin, Michael F. Berger and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO